MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Defence Therapeutics Inc (CSE:DTC)

0.7000 UNCHANGED
Streaming Delayed Price Updated: 3:49 PM EST, Jan 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 0.7000
Bid (Size) 0.7000 (4,500)
Ask (Size) 0.7200 (1,000)
Prev. Close 0.7000
Today's Range 0.7000 - 0.7000
52wk Range 0.5500 - 1.660
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Life Sciences Virtual Investor Forum Agenda Announced for December 11th
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Precision Medicine Helps Conquer Advanced-Stage Cancer
As North America reports a dramatic rise in advanced-stage cancer cases, experts are saying that major breakthroughs in oncology could make “now the best time in human history to get cancer.” According... 
Via PressReach

Performance

YTD
N/A
N/A
1 Month
-17.6%
-17.6%
3 Month
-13.6%
-13.6%
6 Month
-1.4%
-1.4%
1 Year
+7.7%
+7.7%

More News

Read More
News headline image
Defence’s Successful Submission of an Investigational New Drug (IND) Application for AccuTOX(R) as an Injectable Anticancer Treatment for Solid Tumors
Via PressReach
Global Oncology Drugs Market Size Projected to Reach $484 Billion by 2030
Via FinancialNewsMedia
News headline image
Defence Therapeutics Key Platform Patent Accepted Broadly Covering Vaccine Technology
Via PressReach
Topics Intellectual Property
Global Cancer Vaccines Market Share Is Expected To Reach $19.27 Billion By 2030
Via FinancialNewsMedia
News headline image
Defence’s Novel Accutox(TM) Continues to Surprise on Results Against Cancer
Via PressReach
News headline image
Bristol Myers Squibb Enters the Multi-Billion-Dollar Oncology Race
Via PressReach
News headline image
Bristol Myers Squibb Joins Big Pharma’s Race to Dominate Oncology
Via PressReach
News headline image
Defence’s Delivery of Encapsulated AccuTOX(TM)-Chitosan Nanoparticles Triggers Complete Tumor Regression in Animals with Pre-Established Solid Lymphoma
Via PressReach
News headline image
Elli Lilly Joins Big Pharma’s Multi-Billion-Dollar Oncology Race
Via PressReach
News headline image
Big Pharma’s Billion-Dollar Bets on Advanced Cancer Therapies
Via PressReach
News headline image
Defence Announces Peer-reviewed Publication of Its Preclinical Data on Accum(R) as an Anti-Cancer Molecule in the Journal of Cancer Science
Via PressReach
News headline image
Defence’s Accum(R)-mRNA Lipid Nanoparticles Elicit Antibody Response 2X Stronger than Standard mRNA Vaccines
Via PressReach
News headline image
BTV Investor Alert - Defence Therapeutics: Developing Immune-Related Therapies for Cancer Treatment
Via Newsfile
News headline image
BTV Features: Champion Iron Limited, Defence Therapeutics, Nouveau Monde Graphite, Talisker Resources, Osisko Development & more on FOX Business News
Via Newsfile
Topics Supply Chain
News headline image
BTV Features: Defence Therapeutics, Volatus Aerospace, NGEx Minerals, York Harbour Metals, & AuTECO Minerals
Via Newsfile
News headline image
Defence Therapeutics Is Granted Patents in Japan and Israel Expanding Its Novel ADC Platform Technology in the Fast Growing Antibody-Drug Conjugates Market
Via Newsfile
Topics Death Intellectual Property
News headline image
Breakthrough Results with Accum(TM) A1-Reprogrammed MSC, Mesenchymal Stem Cells, in a Novel Vaccine Cured 80% of Animals with Pre-Established Lymphoma
Via Newsfile
News headline image
Defence Therapeutics Applauds United States President Biden Cancer Moonshot Initiative
Via Newsfile
News headline image
The Antibody Response Induced by Defence Therapeutics AccuVAC-PT001 Vaccine Cross-Reacts with All Tested SARS-CoV-2 Variants
Via Newsfile
News headline image
Defence Therapeutics Signs a Collaboration Agreement with the Curie Institute for Testing the Accum-T-DM1 ADC Therapeutic in PDX Models of Breast Cancer
Via Newsfile
News headline image
Defence Therapeutics AccuTOX Exhibits Potent Anti-Cancer Properties
Via Newsfile
News headline image
Defence Therapeutics Retains the HUS Comprehensive Cancer Center to Optimize Its Accum-T-DM1 ADC Therapeutic
Via Newsfile
News headline image
RETRANSMISSION: Defence Therapeutics Advances in Pre-Clinical Testing of Its Infectious Disease Vaccine Program
Via Newsfile

Frequently Asked Questions

Is Defence Therapeutics Inc publicly traded?
Yes, Defence Therapeutics Inc is publicly traded.
What exchange does Defence Therapeutics Inc trade on?
Defence Therapeutics Inc trades on the Canadian Securities Exchange
What is the ticker symbol for Defence Therapeutics Inc?
The ticker symbol for Defence Therapeutics Inc is DTC on the Canadian Securities Exchange
What is the current price of Defence Therapeutics Inc?
The current price of Defence Therapeutics Inc is 0.7000
When was Defence Therapeutics Inc last traded?
The last trade of Defence Therapeutics Inc was at 01/07/26 03:49 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story